This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The study was sponsored by Merck, Sharp and Dohme (MSD) France.
Emery C, et al. Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database. Diabetes Therapy : Jan 2020. Available from: URL: http://doi.org/10.1007/s13300-020-00760-x
About this article
Cite this article
Dipeptidyl peptidase 4 inhibitors reduce costs in T2DM management. PharmacoEcon Outcomes News 846, 12 (2020). https://doi.org/10.1007/s40274-020-6551-9